In the phase II trial, many patients with Alzheimer's disease got no worse over two full years, and in some cases, patients treated with Flurizan appear to have improved, according to the US biopharmaceutical company.
At 24 months, study participants in the phase II trial with mild Alzheimer's disease taking 800 mg twice daily Flurizan experienced a 67% improvement in their level of cognitive decline compared with placebo, as measured by the Mini Mental State Exam (MMSE) score. Additionally, 42% of patients on 800 mg twice daily Flurizan experienced improvement or zero decline, compared with 14% of patients taking placebo.
“The 24 month phase II responder analysis provides further evidence of efficacy against mild Alzheimer's disease that is consistent with our understanding of Flurizan's mechanism of action as a SALA,” said Adrian Hobden, president of Myriad Pharmaceuticals.
“The results support our belief that Flurizan is modifying the course of the underlying disease process.”